Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Travoprost · 1 trial · 1 indication
Number of subjects with Adverse Events including intra-operative and post-operative events (TEAE's) in the study eye
| Arm | Type | Description |
|---|---|---|
| Implantation and Exchange | EXPERIMENTAL | Subjects will undergo implantation and exchange of a Travoprost Intraocular Implant through a small temporal clear corneal incision. |
| Name | Type | Description |
|---|---|---|
| Travoprost | DRUG | Implantation and exchange of a Travoprost Intraocular Implant through a clear corneal incision |
Inclusion Criteria: * Able and willing to attend scheduled follow-up exams for the duration of the study * Able and willing to provide written informed consent on the IRB (institutional review board)/IEC (institutional ethics committee)-approved Informed Consent form * Best spectacle corrected visu...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Glaukos Corp | GKOS | 3 | PHASE4 | Travoprost Intraocular |
| Amneal Pharmaceuticals, Inc. Class A | AMRX | 1 | PHASE4 | Test - Bimatoprost 0.01%, Reference - LUMIGAN |
| AbbVie, Inc. | ABBV | 1 | PHASE4 | Bimatoprost |
| United Therapeutics Corporation | UTHR | 1 | PHASE4 | Nicotinomide |
| Alcon AG | ALC | 3 | PHASE4 | Undisclosed |
Travoprost is an investigational small molecule being studied for the treatment of Open Angle Glaucoma. It is administered as an intraocular implant designed for exchange. The drug is currently in Phase 2 clinical development and is not yet approved by regulatory authorities.
Travoprost is a prostaglandin analog that targets the prostaglandin F2-alpha receptor. By activating this receptor, it increases aqueous humor outflow from the eye, which helps reduce intraocular pressure in patients with Open Angle Glaucoma.
Travoprost is being developed by Glaukos Corporation, a company publicly traded under the ticker symbol GKOS. Glaukos specializes in ophthalmology and is advancing this intraocular implant for the treatment of Open Angle Glaucoma.
Travoprost is currently in Phase 2 clinical development. It is an investigational drug and has not received FDA approval. The Phase 2 trial has been completed, and the drug remains under investigation for Open Angle Glaucoma.
Travoprost has one completed Phase 2 clinical trial registered under NCT04615403, titled 'Study of Exchange of Travoprost Intraocular Implant.' The trial enrolled 33 participants with Open Angle Glaucoma and was conducted in the United States and Philippines.
Yes, Travoprost is a prostaglandin analog. It works by targeting the prostaglandin F2-alpha receptor to enhance aqueous humor outflow and lower intraocular pressure. This mechanism is being evaluated in an intraocular implant for Open Angle Glaucoma.